Lucentis is an antibody fragment approved for the treatment of neovascular (wet) age-related macular degeneration (AMD). Lucentis is the only approved treatment for wet AMD proven to improve or maintain vision. Wet AMD is characterized by a loss of function in the portion of the eye responsible for central vision and is highly correlated with aging. Lucentis has become the “gold standard” for treating wet AMD and can be used at various intervention points in first-line and second-line therapy. Lucentis is marketed in the United States by Genentech and in the rest of the world by Novartis.
How Lucentis Works
Lucentis binds and inhibits vascular endothelial growth factor-A (VEGF-A), a protein critical to the formation of new, leaky blood vessels in the back of the eye that cause damage to the macula, which contains a high density of photoreceptors responsible for visual acuity.
Lucentis was approved for wet AMD in the US in 2006 and in the EU in 2007. Wet AMD is the leading cause of blindness in persons over 60 years of age in the developed world.